Adolescent alcohol use is associated with myriad adverse legal, health, and educational consequences and contributes to the leading causes of mortality among youth. Yet despite the magnitude of this public health problem, treatment initiatives for youth remain inadequate. Given these data, the National Institute on Alcohol Abuse and Alcoholism identified the critical need for medications development research for youth (PA-10-100) with the goal of identifying promising agents for which large-scale clinical trials are justified. The long-term goal of this research program, now in its 20th year, is to improve pharmacotherapy for alcoholism. The major objective of this competing continuation (renewal) application is to address the urgent need for empirical data on medications that may benefit youth. For the past 10 years our research program has successfully paired human laboratory paradigms with ecological momentary assessment (EMA), whereby research participants use handheld electronic diaries to monitor their drinking, craving, and sensitivity to alcohol in real time in their natural environment Using this approach, we identified mechanisms by which medications act and patient characteristics that moderate these effects. The proposed study will test if and how topiramate (TPM), an anticonvulsant shown to be efficacious for treating adults, reduces drinking in youth To this end, we will randomize adolescents with AD (n = 160;ages 14-20) to TPM or placebo for 8 weeks, in combination with biweekly motivational enhancement therapy sessions, using a two-group, double-blind design. While at the target dose (200 mg/day) youth will complete EMA for 4 weeks in their natural environmentIn addition, youth will complete alcohol cue reactivity assessments in the laboratory to test the effects of TPM on cue-elicited craving and physiological reactivity in a controlled environmentYouth will complete 6- and 12-month follow-up assessments to determine whether any benefits are sustained. This study will provide much needed data on the tolerability and efficacy of TPM with adolescents, while adding important new information about the biobehavioral mechanisms of TPM action in youth.
This study will help to determine whether the medication, topiramate, reduces alcohol use among adolescents with alcohol dependence. It will also help answer the question, How does topiramate reduce drinking in youth? Understanding how topiramate may reduce drinking in adolescents would allow for a more targeted pharmacotherapeutic approach to treatment and help to identify additional medications that may hold promise for improving treatment outcomes for youth.
|Miranda Jr, Robert; Monti, Peter M; Ray, Lara et al. (2014) Characterizing subjective responses to alcohol among adolescent problem drinkers. J Abnorm Psychol 123:117-29|
|Miranda Jr, Robert; MacKillop, James; Treloar, Hayley et al. (2014) Biobehavioral mechanisms of topiramate's effects on alcohol use: an investigation pairing laboratory and ecological momentary assessments. Addict Biol :|
|Ramirez, Jason; Miranda Jr, Robert (2014) Alcohol craving in adolescents: bridging the laboratory and natural environment. Psychopharmacology (Berl) 231:1841-51|
|Dolan, Sara L; Rohsenow, Damaris J; Martin, Rosemarie A et al. (2013) Urge-specific and lifestyle coping strategies of alcoholics: Relationships of specific strategies to treatment outcome. Drug Alcohol Depend 128:8-14|
|MacKillop, James; Miranda Jr, Robert; Monti, Peter M et al. (2010) Alcohol demand, delayed reward discounting, and craving in relation to drinking and alcohol use disorders. J Abnorm Psychol 119:106-14|
|Ray, Lara A; Miranda Jr, Robert; Tidey, Jennifer W et al. (2010) Polymorphisms of the mu-opioid receptor and dopamine D4 receptor genes and subjective responses to alcohol in the natural environment. J Abnorm Psychol 119:115-25|
|Mackillop, James; Murphy, James G; Tidey, Jennifer W et al. (2009) Latent structure of facets of alcohol reinforcement from a behavioral economic demand curve. Psychopharmacology (Berl) 203:33-40|
|Ray, Lara A; Miranda Jr, Robert; MacKillop, James et al. (2009) A preliminary pharmacogenetic investigation of adverse events from topiramate in heavy drinkers. Exp Clin Psychopharmacol 17:122-9|
|McGeary, John (2009) The DRD4 exon 3 VNTR polymorphism and addiction-related phenotypes: A review. Pharmacol Biochem Behav :|
|Tidey, Jennifer W; Monti, Peter M; Rohsenow, Damaris J et al. (2008) Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment. Alcohol Clin Exp Res 32:58-66|
Showing the most recent 10 out of 29 publications